These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6384817)

  • 1. Systemic alpha-interferon therapy of multiple sclerosis.
    Knobler RL; Panitch HS; Braheny SL; Sipe JC; Rice GP; Huddlestone JR; Francis GS; Hooper CK; Kamin-Lewis RM; Johnson KP
    Neurology; 1984 Oct; 34(10):1273-9. PubMed ID: 6384817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.
    Camenga DL; Johnson KP; Alter M; Engelhardt CD; Fishman PS; Greenstein JI; Haley AS; Hirsch RL; Kleiner JE; Kofie VY
    Arch Neurol; 1986 Dec; 43(12):1239-46. PubMed ID: 3535752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic interferon therapy of multiple sclerosis: the pros.
    Knobler RL
    Neurology; 1988 Jul; 38(7 Suppl 2):58-61. PubMed ID: 3133575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study.
    Jacobs L; Salazar AM; Herndon R; Reese PA; Freeman A; Jozefowicz R; Cuetter A; Husain F; Smith WA; Ekes R
    Arch Neurol; 1987 Jun; 44(6):589-95. PubMed ID: 3579676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The placebo effect during a double blind trial of recombinant alpha 2 interferon in multiple sclerosis patients: immunological and clinical findings.
    Hirsch RL; Johnson KP; Camenga DL
    Int J Neurosci; 1988 Apr; 39(3-4):189-96. PubMed ID: 3045033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis.
    Jacobs L; Salazar AM; Herndon R; Reese PA; Freeman A; Josefowicz R; Cuetter A; Husain F; Smith WA; Ekes R
    Lancet; 1986 Dec 20-27; 2(8521-22):1411-3. PubMed ID: 2878272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha interferon clinical trial for multiple sclerosis: design considerations.
    Alter M; Greenstein J; Camenga D; LaRue L
    Neuroepidemiology; 1987; 6(1-2):85-92. PubMed ID: 3306431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.
    Durelli L; Bongioanni MR; Cavallo R; Ferrero B; Ferri R; Ferrio MF; Bradac GB; Riva A; Vai S; Geuna M
    Neurology; 1994 Mar; 44(3 Pt 1):406-13. PubMed ID: 8145906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation.
    Kastrukoff LF; Oger JJ; Hashimoto SA; Sacks SL; Li DK; Palmer MR; Koopmans RA; Petkau AJ; Berkowitz J; Paty DW
    Neurology; 1990 Mar; 40(3 Pt 1):479-86. PubMed ID: 2179764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial of natural alpha interferon in multiple sclerosis.
    Knobler RL; Panitch HS; Braheny SL; Sipe JC; Rice GP; Huddlestone JR; Francis GS; Hooper CJ; Kamin-Lewis RM; Johnson KP
    Ann N Y Acad Sci; 1984; 436():382-8. PubMed ID: 6398020
    [No Abstract]   [Full Text] [Related]  

  • 11. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.
    Lycke J; Svennerholm B; Hjelmquist E; Frisén L; Badr G; Andersson M; Vahlne A; Andersen O
    J Neurol; 1996 Mar; 243(3):214-24. PubMed ID: 8936350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon therapy for condylomata acuminata.
    Eron LJ; Judson F; Tucker S; Prawer S; Mills J; Murphy K; Hickey M; Rogers M; Flannigan S; Hien N
    N Engl J Med; 1986 Oct; 315(17):1059-64. PubMed ID: 3531860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrathecal interferon in multiple sclerosis.
    Jacobs L; O'Malley J; Freeman A; Murawski J; Ekes R
    Arch Neurol; 1982 Oct; 39(10):609-15. PubMed ID: 6751302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.
    Bornstein MB; Miller A; Slagle S; Weitzman M; Crystal H; Drexler E; Keilson M; Merriam A; Wassertheil-Smoller S; Spada V
    N Engl J Med; 1987 Aug; 317(7):408-14. PubMed ID: 3302705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of recombinant alpha 2-interferon on defective natural killer cell activity in multiple sclerosis.
    Hirsch RL; Johnson KP
    Neurology; 1985 Apr; 35(4):597-600. PubMed ID: 3982654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon.
    Hayden FG; Albrecht JK; Kaiser DL; Gwaltney JM
    N Engl J Med; 1986 Jan; 314(2):71-5. PubMed ID: 3001519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group.
    J Neurol Neurosurg Psychiatry; 1989 May; 52(5):566-74. PubMed ID: 2659737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon beta for primary progressive multiple sclerosis.
    Rojas JI; Romano M; Ciapponi A; Patrucco L; Cristiano E
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006643. PubMed ID: 19160292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.